These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 24689946)

  • 1. Belimumab may not prevent lupus nephritis in serologically active patients with ongoing non-renal disease activity.
    Sjöwall C; Cöster L
    Scand J Rheumatol; 2014; 43(5):428-30. PubMed ID: 24689946
    [No Abstract]   [Full Text] [Related]  

  • 2. Effect of belimumab treatment on renal outcomes: results from the phase 3 belimumab clinical trials in patients with SLE.
    Dooley MA; Houssiau F; Aranow C; D'Cruz DP; Askanase A; Roth DA; Zhong ZJ; Cooper S; Freimuth WW; Ginzler EM;
    Lupus; 2013 Jan; 22(1):63-72. PubMed ID: 23263865
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New onset of lupus nephritis in two patients with SLE shortly after initiation of treatment with belimumab.
    Staveri C; Karokis D; Liossis SC
    Semin Arthritis Rheum; 2017 Jun; 46(6):788-790. PubMed ID: 27793432
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Belimumab for the treatment of systemic lupus erythematosus.
    Jordan N; D'Cruz DP
    Expert Rev Clin Immunol; 2015 Feb; 11(2):195-204. PubMed ID: 25543845
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Disease control and safety of belimumab plus standard therapy over 7 years in patients with systemic lupus erythematosus.
    Ginzler EM; Wallace DJ; Merrill JT; Furie RA; Stohl W; Chatham WW; Weinstein A; McKay JD; McCune WJ; Zhong ZJ; Freimuth WW; Petri MA;
    J Rheumatol; 2014 Feb; 41(2):300-9. PubMed ID: 24187095
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Systemic lupus erythematosus exacerbation following cessation of belimumab treatment.
    Furer V; Zisman D; Pokroy-Shapira E; Molad Y; Elkayam O; Paran D
    Scand J Rheumatol; 2016; 45(2):103-6. PubMed ID: 26515057
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy, pharmacokinetic and pharmacodynamic profile of belimumab for systemic lupus erythematosus.
    Jordan NP; D'Cruz DP
    Expert Opin Drug Metab Toxicol; 2015; 11(10):1635-45. PubMed ID: 26327145
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of Belimumab for active lupus nephritis in a young Hispanic woman intolerant to standard treatment: a case report.
    Fontana F; Alfano G; Leonelli M; Cerami C; Ligabue G; Spinella A; Citriniti G; Manzini CU; Ferri C; Cappelli G
    BMC Nephrol; 2018 Oct; 19(1):276. PubMed ID: 30342482
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Belimumab in systemic lupus erythematosus: a guide for its use in the daily practice].
    Ramos-Casals M; Ruiz-Irastorza G; Jiménez-Alonso J; Khamashta MA;
    Rev Clin Esp (Barc); 2013; 213(1):66-7. PubMed ID: 23565550
    [No Abstract]   [Full Text] [Related]  

  • 10. Refractory subacute cutaneous lupus erythematous responding to a single course of belimumab: a new anti-BLyS human monoclonal antibody.
    Husein-ElAhmed H; Callejas-Rubio JL; Rios-Fernandez R; Ortego-Centeno N
    Indian J Dermatol Venereol Leprol; 2014; 80(5):477-8. PubMed ID: 25201862
    [No Abstract]   [Full Text] [Related]  

  • 11. Recent advances in the treatment of systemic lupus erythematosus with belimumab in children.
    Deng WP
    Zhongguo Dang Dai Er Ke Za Zhi; 2021 Oct; 23(10):1069-1074. PubMed ID: 34719425
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Thrombotic microangiopathy with refractory lupus nephritis successfully treated by combining rituximab with belimumab.
    Hanai S; Kobayashi Y; Ito R; Harama K; Nakagomi D
    Scand J Rheumatol; 2023 Mar; 52(2):227-229. PubMed ID: 36409225
    [No Abstract]   [Full Text] [Related]  

  • 13. Use of belimumab throughout pregnancy to treat active systemic lupus erythematosus: a case report.
    Danve A; Perry L; Deodhar A
    Semin Arthritis Rheum; 2014 Oct; 44(2):195-7. PubMed ID: 25005336
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety profile of belimumab: pooled data from placebo-controlled phase 2 and 3 studies in patients with systemic lupus erythematosus.
    Wallace DJ; Navarra S; Petri MA; Gallacher A; Thomas M; Furie R; Levy RA; van Vollenhoven RF; Cooper S; Zhong ZJ; Freimuth W; Cervera R;
    Lupus; 2013 Feb; 22(2):144-54. PubMed ID: 23213069
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Durable renal response and safety with add-on belimumab in patients with lupus nephritis in real-life setting (BeRLiSS-LN). Results from a large, nationwide, multicentric cohort.
    Gatto M; Saccon F; Andreoli L; Bartoloni E; Benvenuti F; Bortoluzzi A; Bozzolo E; Brunetta E; Canti V; Cardinaletti P; Ceccarelli F; Ciccia F; Conti F; De Marchi G; de Paulis A; De Vita S; Emmi G; Faggioli P; Fasano S; Fredi M; Gabrielli A; Gasparotto M; Gerli R; Gerosa M; Govoni M; Gremese E; Laria A; Larosa M; Mosca M; Orsolini G; Pazzola G; Petricca L; Ramirez GA; Regola F; Rossi FW; Rossini M; Salvarani C; Scarpato S; Tani C; Tincani A; Ubiali T; Urban ML; Zen M; Doria A; Iaccarino L
    J Autoimmun; 2021 Nov; 124():102729. PubMed ID: 34600347
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Post-marketing experiences with belimumab in the treatment of SLE patients.
    Askanase AD; Yazdany J; Molta CT
    Rheum Dis Clin North Am; 2014 Aug; 40(3):507-17, viii. PubMed ID: 25034159
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of Telitacicept in a systemic lupus erythematosus patient with suboptimal response to Belimumab: A case report.
    Huang L; Qian G; Zhang H; Li Q; Chen L; Tang X; Zhao H
    Lupus; 2024 Feb; 33(2):172-175. PubMed ID: 38081170
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The use of belimumab in three cases of refractory lupus nephritis.
    Malaweera A; Dayan S; Pellicano R; Hoi A; Kitching AR; Kent JR
    Intern Med J; 2023 Oct; 53(10):1901-1906. PubMed ID: 37859540
    [TBL] [Abstract][Full Text] [Related]  

  • 19. De novo lupus nephritis during treatment with belimumab.
    Parodis I; Vital EM; Hassan SU; Jönsen A; Bengtsson AA; Eriksson P; Leonard D; Gunnarsson I; Rönnblom L; Sjöwall C
    Rheumatology (Oxford); 2021 Sep; 60(9):4348-4354. PubMed ID: 33341888
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Successful treatment of refractory lupus nephritis by the sequential use of rituximab and belimumab.
    Simonetta F; Allali D; Roux-Lombard P; Chizzolini C
    Joint Bone Spine; 2017 Mar; 84(2):235-236. PubMed ID: 27238199
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.